Real-time · AI · Cross-signal
XyloCor Therapeutics, Inc. just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on XyloCor Therapeutics, Inc., plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
XyloCor Therapeutics and SmartCella Enter Licensing Agreement for Extroducer Infusion Catheter System
Jul 10, 2024•almost 2 years ago
Contract Type
agreement
WayneBiotechnologyDescription
XyloCor Therapeutics, Inc. and SmartCella Holding AB have entered into a licensing agreement where XyloCor has obtained the rights to the Extroducer Infusion Catheter System for the delivery of its lead gene therapy candidate, XC001, directly into the heart for patients with refractory angina, aiming to offer improved safety and ease of delivery without surgery.
Related People
Suggested for you
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months